Neurobo Pharmaceuticals Ptb Ratio Over Time
| NRBO Stock | USD 2.37 0.02 0.85% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Neurobo Pharmaceuticals Performance and Neurobo Pharmaceuticals Correlation. Neurobo |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurobo Pharmaceuticals. If investors know Neurobo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurobo Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.29) | Return On Assets (0.74) | Return On Equity (1.61) |
The market value of Neurobo Pharmaceuticals is measured differently than its book value, which is the value of Neurobo that is recorded on the company's balance sheet. Investors also form their own opinion of Neurobo Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Neurobo Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurobo Pharmaceuticals' market value can be influenced by many factors that don't directly affect Neurobo Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurobo Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurobo Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurobo Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Ptb Ratio Analysis
Compare Neurobo Pharmaceuticals and related stocks such as Allarity Therapeutics, Hillstream Biopharma, and Virax Biolabs Group Ptb Ratio Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALLR | 1.8953 | 1.8953 | 1.8953 | 1.8953 | 1.8953 | 1.8953 | 1.8953 | 1.8953 | 1.8953 | 1.8953 | 1.2767 | 3.5121 | 1.481 | (239.3 K) | (227.3 K) |
| VRAX | (196) | (196) | (196) | (196) | (196) | (196) | (196) | (196) | (196) | (196) | (347) | (212) | 0.81 | 0.2748 | 0.29 |
| QNRX | 0.5743 | 0.5743 | 0.5743 | 0.5743 | 0.5743 | 0.5743 | 1.9022 | 7.2167 | 3.6473 | 1.099 | (3.9276) | 10.9756 | 0.9292 | 0.781 | 0.74 |
| BDRX | 12.1771 | 12.1771 | 12.1771 | 12.1771 | 12.1771 | 12.1771 | 12.1771 | 12.1771 | 12.1771 | 12.1771 | 43.6394 | 29.8899 | 25.4516 | 0.3557 | 0.34 |
| ZURA | 26.6802 | 26.6802 | 26.6802 | 26.6802 | 26.6802 | 26.6802 | 26.6802 | 26.6802 | 26.6802 | 26.6802 | 26.6802 | 26.6802 | (3.896) | 2.4242 | 2.3 |
| PHIO | (0.0032) | (0.0032) | (2.0322) | 6.8869 | 12.7977 | 2.8048 | 0.4437 | 6.8374 | 0.1708 | 0.7532 | 0.947 | 0.5844 | 0.4677 | 0.2044 | 0.19 |
| SONN | (14.127) | (14.127) | (14.127) | 26.7252 | (14.127) | 8.3674 | 5.6854 | 4.952 | 4.8792 | 64.0697 | 5.3408 | (20.1031) | (105) | 4.8792 | 5.12 |
| ATNF | 2.204 | 2.204 | 2.204 | 2.204 | 2.204 | 2.204 | 2.204 | 2.204 | (1.9305) | 0.4428 | 1.6099 | 3.0904 | 0.5678 | (12.0465) | (11.44) |
| CDIO | 1.5 K | 1.5 K | 1.5 K | 1.5 K | 1.5 K | 1.5 K | 1.5 K | 1.5 K | 1.5 K | 1.5 K | 1.5 K | 10.6945 | 0.7608 | 10.6777 | 10.14 |
| REVB | (24.4 K) | (24.4 K) | (24.4 K) | (24.4 K) | (24.4 K) | (24.4 K) | (24.4 K) | (24.4 K) | (24.4 K) | (24.4 K) | 26.8001 | (1 K) | 3.4078 | 0.5151 | 0.54 |
| KPRX | (6.9974) | (6.9974) | (6.9974) | (6.4231) | (8.0075) | 24.9721 | (393) | (71.2639) | 16.621 | 43.3167 | 29.1053 | 14.2078 | 1.9817 | 0.4139 | 0.43 |
Neurobo Pharmaceuticals and related stocks such as Allarity Therapeutics, Hillstream Biopharma, and Virax Biolabs Group Ptb Ratio description
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.My Equities
My Current Equities and Potential Positions
| Neurobo Pharmaceuticals | NRBO |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 2.37
Check out Neurobo Pharmaceuticals Performance and Neurobo Pharmaceuticals Correlation. To learn how to invest in Neurobo Stock, please use our How to Invest in Neurobo Pharmaceuticals guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Neurobo Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.